🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

67 results for “ADC” Clear

  1. ADCT-402

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  2. ADCT-402

    ADC Therapeutics SA

    Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  3. ADCT-502

    ADC Therapeutics SA

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  4. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials

  5. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  6. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  7. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  8. Camidanlumab tesirine

    ADC Therapeutics SA

    Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  9. Carmustine

    ADC Therapeutics SA

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  10. HWK-016, MUCIN-16-targeted ADC

    CATALYST PHARMACEUTICALS, INC.

    PROC

    phase 1 small molecule active

    1 trial

  11. Loncastuximab Tesirine

    ADC Therapeutics SA

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  12. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  13. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  14. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

  15. VRON-0200-AdC6

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab active

    1 trial

  16. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Idiopathic Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  17. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  18. VY-AADC02

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  19. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo Europe GmbH

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources